Susan McGaurn

In her role, Dr. McGaurn will spearhead strategic medical affairs efforts that will support the launch of oteseconazole (VT-1161), an oral antifungal product candidate for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC) that is currently in Phase 3 clinical development.

Dr. McGaurn has spent more than 20 years in medical science roles in the pharmaceutical industry. The breadth of her experience has contributed to the successful establishment and execution of multiple field-based Medical Science Liaison (MSL) launch teams in highly scientific therapeutic areas. She has led the operations of various Medical Information Call Centers and has headed the strategic advancement of policies and procedures in numerous biopharmaceutical organizations. Dr. McGaurn started her career as a clinical pharmacist in several Clinical Research Centers funded by the National Institutes of Health. Previously, Dr. McGaurn served as Director, Medical Information and Call Centers at Endo Pharmaceuticals.